Banking & Financing Solutions for Life Science and Biotech Companies

Key Takeaways

• Life science and biotech companies have distinct financing needs at every stage, from early R&D through clinical development and commercial launch.
• Debt and equity serve different purposes in a life sciences capital structure. Knowing when to use each and how they interact with your runway and milestone timeline is as important as knowing what’s available.
• The right biotech banking relationship means your banker already understands development-stage company financials, venture backing and what a clinical milestone means for your capital needs. You shouldn’t have to explain the basics.
• Working capital lines, term loans and venture debt can all play a role in extending runway, bridging between rounds or funding a commercial buildout without giving up additional equity.

Why biotech banking is different

Life science and biotech companies don’t follow a conventional business trajectory. Revenue may be years away. Capital needs shift with clinical results. A successful financing round can change your balance sheet overnight. And the regulatory environment shapes everything from your timeline to your market opportunity.

Conventional business banking wasn’t designed for that. Biotech banking is.

Working with a bank that understands the life sciences capital cycle — venture backing, development-stage financials, milestone-driven inflection points — means your financing conversations start from a more useful place. Less time on context, more time on structure.

Financing options for life science and biotech companies

Term loans:

A term loan provides a defined amount of capital upfront, repaid over a fixed period with either a fixed or variable interest rate. For biotech and life sciences companies, term loans are commonly used for equipment purchases, facility build-outs, manufacturing scale-up and research infrastructure. They work particularly well when the use of proceeds is specific and the repayment timeline aligns with your projected cash flow or when you have a clear bridge between your current position and the next funding event.

Working capital lines of credit:

A revolving line of credit gives biotech companies on-demand access to funds up to a set limit: draw what you need, repay it, draw again. This structure is well suited to the uneven cash flow patterns common in life sciences, where expenses don’t pause between milestones and receivables from grants, partnerships or early commercial activity can be lumpy. For development-stage companies, having a working capital facility in place before you need it is often the difference between a managed cash gap and a reactive fundraise.

SBA loans:

For qualifying life sciences companies, SBA-guaranteed loans offer flexible financing for working capital, equipment, facility acquisition and more often with favorable terms relative to conventional lending. They can be a useful option for earlier-stage companies or those looking to preserve equity while funding operational needs.

What good biotech banking actually looks like

Beyond the specific products, the banking relationship itself matters especially in life sciences, where your capital needs evolve quickly and your banker needs to keep up.

A few things that define a productive biotech banking relationship:

• A banker who knows your sector. You shouldn’t have to explain what a Series B looks like, why pre-revenue doesn’t mean pre-value or how a CRO contract affects your cash flow. A banker with genuine life sciences experience starts from a different baseline.
• Faster decisions when timing matters. Clinical results, partnership opportunities and financing windows don’t wait for a three-week credit committee process. Sector fluency and relationship banking tend to produce faster, more considered decisions.
• A single point of contact. One banker who knows your company, your history and your goals — not a different person every time you call. That consistency is especially valuable as your capital needs shift across development stages.

The Healthcare & Life Sciences practice at Customers Bank

The Healthcare & Life Sciences practice within Customers Bank’s Tech & Venture banking team works specifically with venture-backed biotech, life sciences, digital health, medtech and med device companies. Whether you’re a venture-backed startup navigating your first institutional banking relationship or a later-stage company preparing for a commercial launch, we work with companies across the full venture continuum.

Reach out to the Tech & Venture team →